



Indrayani Biotech Limited

BLOCK NO 1 MODULE NO 32, 33
SIDCO ELECTRONICS COMPLEX
THIRU VI KA INDUSTRIAL ESTATE
GUINDY CHENNAI 600 032

CIN: L40100TN1992PLC129301

14.02.2021

To,

The Manager

Bombay Stock Exchange Limited

Floor 25, P J Tower, Dalal Street,

Mumbai 400001

(Scrip code 526445)

Dear Sir/Madam

Sub: Covering letter for the board meeting

Please find attached the board outcome for the meeting held today i.e. 14.02.2021

Kindly take the same in your record

Thanking you

Yours Sincerely,



KASIRAMAN SAYEE SUNDAR

Managing Director

Din: 01295584



Indrayani Biotech Limited

BLOCK NO 1 MODULE NO 32, 33
SIDCO ELECTRONICS COMPLEX
THIRU VI KA INDUSTRIAL ESTATE
GUINDY CHENNAI 600 032

CIN: L40100TN1992PLC129301

14.02.2021

To,

The Manager

Bombay Stock Exchange Limited

Floor 25, P J Tower, Dalal Street,

Mumbai 400001

(Scrip code 526445)

Dear Sir/Madam

Sub: Intimation on the Outcome for the Board meeting held on 14th February 2021 and Disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

In accordance with Regulation 30 of Listing Regulations, we wish to inform you that the meeting of the Board of Directors of the company (Board) was duly convened today i.e., 14th February 2021 where the Board, inter alia, considered/ noted / took on record the following:

1. To Consider and Approve the unaudited financial results along with the Limited Review Report for the Quarter and Nine months ended 31st December, 2020
2. Investment in shares of Matrix Boilers Private Limited by Indrayani Biotech Limited
3. Any other business with the permission of the Chair.

The meeting commenced at 3.30 pm and concluded at 4.00 pm.

Kindly take the same on record.

Thanking You

Yours Faithfully

KASIRAMAN SAYEE SUNDAR

Managing Director

Din: 01295584



INDRAYANI BIOTECH LIMITED

Regd. Office : #32 & 33 Block: I, 3rd Floor Thiru Vi Ka Industrial Estate, SIDCO Industrial Estate, Guindy, Chennai,
Tamil Nadu 600032.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec 2020

Rs. In Lakhs

Sr No	PARTICULARS	3 months ended 31/12/2020	Year to date figure for the previous year ended 31/12/2019	Year to date figures for current period ended 31/12/2020	Previous Year ended 31/03/2020
		(Unaudited)			
A	Date of start of reporting period	01-10-2020	01-10-2019	01-04-2020	01-04-2019
B	Date of end of reporting period	31-12-2020	31-12-2019	31-12-2020	31-03-2020
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	Income from Operations				
	(a) Net Sales/Revenue from Operations	580.76	50.18	1,392.60	50.18
	(b) Other Income	1.18	-	11.59	
	Total Income from Operations	581.95	50.18	1,404.19	50.18
2	Expenses				
	(a) Cost of Materials consumed	305.40	49.68	1,093.70	49.68
	(b) Employee benefits expenses	112.22		468.87	3.00
	(c) Finance Costs	35.48	1.25	95.90	4.99
	(d) Depreciation and amortisation expense	22.29		64.78	
	(e) Other expenses				
	- Advertisement	0.76	0.54	1.12	2.01
	- Audit Fees	2.00		2.00	0.44
	- Business Promotion	6.98		18.58	0.10
	- Legal & Professional Expenses	5.61	1.29	17.12	4.05
	- Rates & Taxes	1.80		6.99	3.54
	- Telephone & Postage	0.21		1.77	
	- Travelling & Conveyance	7.38	0.64	37.15	2.23
	- Printing & Stationery	0.58	0.15	1.47	0.15
	- Postage & Courier				
	- Rent	6.02		29.88	0.36
	- Bank charges	-	0.01	1.81	0.01
	-Misc Expenses	39.96	(0.12)	150.09	0.17
	Total Other expenses	71.31	2.51	267.98	13.06
	Total Expenses	546.70	53.43	1,991.23	70.73
3	Total profit / (Loss) before exceptional items and tax	35.25	(3.25)	(587.04)	(20.55)
4	Exceptional Items	209.74	-	209.74	-
5	Total profit / (Loss) before tax	(174.49)	(3.25)	(796.78)	(20.55)
7	Tax Expenses				
8	Current Tax				
9	Deferred Tax				
10	Total Tax Expenses				
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	Net Profit Loss for the period from continuing operations	(174.49)	(3.25)	(796.78)	(20.55)
15	Profit (loss) from discontinued operations before tax				
16	Tax expense of discontinued operations				
17	Net profit (loss) from discontinued operation after tax				
19	Share of profit (loss) of associates and joint ventures accounted for using equity method				
21	Total profit (loss) for period	(174.49)	(3.25)	(796.78)	(20.55)
22	Other comprehensive income net of taxes				
23	Total Comprehensive Income for the period				
24	Total profit or loss, attributable to				
	Profit or loss, attributable to owners of parent	(174.49)	(3.25)	(796.78)	(20.55)
	Total profit or loss, attributable to non-controlling interests				



K. durgadevi

25	Total Comprehensive income for the period attributable to				
	Comprehensive income for the period attributable to owners of parent				
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests				
26	Details of equity share capital				
	Paid-up equity share capital	3,422.72	364.39	3,422.72	364.39
	Face value of equity share capital	10.00	10.00	10.00	10.00
27	Details of debt securities				
	Paid-up debt capital				
	Face value of debt securities				
28	Reserves excluding revaluation reserve				
29	Debenture redemption reserve				
30	Earnings per share				
i	Earnings per equity share for continuing operations				
	Basic earnings (loss) per share from continuing operations	(0.51)	(0.09)	(2.33)	(0.56)
	Diluted earnings (loss) per share from continuing operations	(0.51)	(0.09)	(2.33)	(0.56)
ii	Earnings per equity share for discontinued operations				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	Earnings per equity share				
	Basic earnings (loss) per share from continuing and discontinued operations	(0.51)	(0.09)	(2.33)	(0.56)
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.51)	(0.09)	(2.33)	(0.56)
31	Debt equity ratio				
32	Debt service coverage ratio				
33	Interest service coverage ratio				
34	Disclosure of notes on financial results				

1. The stand alone financial results are being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 14-02-2021. The above financial results are subject to limited review by the Statutory Auditors

3. The Company operates in single business segment. Hence no segment wise reporting figures are published

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.



K. Sayee Sundar

Place :Chennai
Date:14-02-2021

K SAYEE SUNDAR
MANAGING DIRECTOR
DIN:01295584



Limited Review Report on Quarterly Financial Results of Indrayani Biotech Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


**Review Report to the Board of Directors,
Indrayani Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Indrayani Biotech Limited** ('the Company') for the quarter ended December 31 2020. This statement, is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the applicable Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Venkatesh & Co
Chartered Accountants
F.R.No.004636S


CA Dasaraty V

Partner
M.No.026336



Place : Chennai
Date : 14th February 2021.
UDIN: 21026336AAAADA2977